Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

What’s New

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

What’s New

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

Saudi Arabia Mandates Pharmaco-Economic Assessments…

Pharmacoeconomic assessments are set to become mandatory in Saudi Arabia starting from July 2025. The Saudi Food and Drug Authority (SFDA) will require manufacturers to submit a budget-impact analysis or a type of cost analysis (-effectiveness, -minimization, -utility, or -benefit), as well as a market share and marketing plan alongside these assessmentsAdditionally, decisions made by other HTA bodies like the National Institute for Health and Care Excellence (NICE), Canada’s Drug Agency (CDA), and France’s High Health Authority (HAS) will play a significant role, as the SFDA now mandates companies to submit data from these HTA assessment bodies, with CDA being particularly influentialManufacturers must be meticulous in preparing and submitting relevant data according to these new requirements for a successful application. This is a change from the previous system, where omissions in price certificate forms could be negotiated during the appeals process to achieve a final price

Germany Edges Closer to Confidential Pricing Option

Last week, the Health Committee (Bundestag) approved the Federal Government's Medical Research Act (MFG), with some amendments. The major point of contention—the proposal for confidential reimbursement amounts for new patent-protected drugs—was adjusted to clarify that only pharmaceutical companies with German research departments will qualify, drug makers have five days to choose between confidential or transparent pricing, and choosing confidentiality comes with a standardized 9% discount on the agreed priceAccording to Alan Crowther, EVERSANA's General Manager of Global Pricing, Access, and Digital Solutions, there are key implications that immediately surface, and the move signifies that "Confidentiality as an option may be increasing somewhat in health systems around the world, but at a cost to manufacturers"Read on to understand more about the consequences of this major change in Germany

Bundestag Backs Amended Medical Research Act

The Federal Government's Medical Research Act (MFG) in Germany has been approved by the Health Committee (Bundestag), after endorsing 26 amendments proposed by the coalitionInterestingly, the contentious issue of confidential pricing for new patent-protected drugs has been revised and clarified: Only pharmaceutical companies with German research departments will qualify, drug makers have five days to choose between confidential or transparent pricing, and choosing confidentiality comes with a standardized 9% discount on the agreed priceThe final outcome of the MFG will depend on the upcoming plenary session vote

EU Pharma Package: What do Member States Currently…

Hungary, which will hold the EU presidency from July to December 2024, will play a crucial role in implementing the European pharmaceutical legislation review and the joint EU health technology assessment (HTA) initiative. Technical discussions about the legislation resume on 3 and 4 July under the Hungarian Presidency, although some MEPs are worried about Hungary's credibility in fulfilling its role given its “lack of compliance with EU law and values and the principle of sincere cooperation"The changes, aimed for initiation in 2024, intend to reduce the protection duration from eight to six years. While countries such as Denmark, Italy, and Sweden criticized the unpredictability this creates, Spain and Portugal support a shorter duration of seven yearsThe European Commission also suggests a hybrid approach to ensure pharmaceutical companies supply the European market. The Parliament favors incentives without mandatory supply requirements, with countries like Austria supporting this model. However, Latvia supports the Commission's original proposal, arguing it considers the unique aspects of national healthcare systems, while others like Estonia and the Czech Republic express skepticism or call for a more company-led initiative

LAST WEEK IN REVIEW

The European Commission released two guidance documents for the joint clinical assessments (JCA) under the EU Health Technology Assessment Regulation (HTAR): "Guidance on Outcomes for JCA" and "Guidance on Reporting Requirements for Multiplicity Issues and Subgroup, Sensitivity, and Post Hoc Analyses in JCAs"In a final draft guidance, the National Institute for Health and Care Excellence (NICE) has not recommended Sanofi’s Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone for treating adult patients with relapsed and refractory multiple myeloma who have undergone at least two prior therapies and have shown disease progression on their last treatment - Sanofi has announced plans to appeal the decision, highlighting that it creates a disparity in access to the Sarclisa regimen, as it remains available in Scotland and Northern IrelandThe National Healthcare Security Administration (NHSA) of China published an updated plan for formulating the latest version of the National Reimbursement Drug List (NRDL)

EU Member States Clash Over Proposed Incentives System…

The Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council has convened to discuss the incentives system within the proposed pharma package, addressing key issues such as regulatory data protection periods, market protection, and the criteria for extending these periodsThe issue of unaddressed medical needs was touched upon, with Ireland noting confusion over the distinction between unmet and high unmet needs. Countries like Croatia and the Netherlands showed a preference for maintaining the current 11-year regulatory data protection cap and wanted to avoid unnecessary burdens. Meanwhile, the importance of a predictable regulatory framework was highlighted by multiple countries"I think it's fair to say we have crystallized the discussion into two remaining options, basically," emphasized the Belgian Health Minister & representative of the Belgian Presidency, Frank Vandenbroucke. "On the one hand, we note support for an incentive based on efforts made by the company to facilitate access. Yet, here, I should note that there is still a discussion on whether modulation should be preferably based on market protection or data protection. We note support for an incentive based on efforts made by the company to facilitate access. Yet here I should note that there is still discussion whether modulation should be preferably on market protection or on data protection"

Vertex, NHS Finally Strike Extended Long-Term Deal for…

NHS England has finally reached a long-term deal with Vertex Pharmaceuticals, making company's cystic fibrosis (CF) medicines permanently available for children and adults in EnglandThe agreement marks the end of a long-standing dispute between Vertex and NICE over the high cost of these drugs and covers Vertex’s entire CF medicine portfolio, including Kaftrio, Symkevi and Orkambi. Although NICE initially rejected the portfolio last November due to cost-effectiveness concerns, it changed its mind in final draft guidance, given the severity of CF and the positive impact of these drugs on the patients' quality and length of lifeVertex is now trying to secure similar agreements in Scotland, Wales and Northern Ireland. Meanwhile, the company is discussing with NHS England and NICE about its next-generation CF treatment, known as vanza triple, which is expected to file for global approval by mid-2024

Stakeholders Discuss Targeted Adjustments to Spain’s…

At the recent VI Meeting of Experts in Health Management and Health Economics, health experts discussed the necessity to update Spain's “Law on Guarantees and Rational Use of Medicines and Health Products”One key focus point was improving the financing and pricing of medicines in Spain. It was noted that the majority of these changes could be achieved through a royal decree rather than an overhaul of the Guarantees Law.The panel pointed out the regulatory challenges and political stagnation affecting the proposed changes. The experts discussed the role of the Interministerial Commission on Drug Prices (CIPM) and the technological evaluation system related to drug prices, and addressed three key aspects of the reference price system (SPR) that needed attention, including the ability to revise prices upward, the negative impact on medications that improve bioavailability, and the disadvantage for medications with lower initial doses

LAST WEEK IN REVIEW

As the UK general election campaigns are underway, the Conservative Party has touted in its manifesto that it will remove bureaucratic obstacles to the use of new medicines, such as the National Health Service (NHS) Budget Impact Test, and align NHS England’s cost-effectiveness thresholds for new medicine indications with those used by the National Institute for Health and Care Excellence (NICE)Blue Cross Blue Shield (BCBS) of Michigan will stop covering weight-loss drugs for its fully insured large group commercial members beginning January 1, 2025The European Federation of Pharmaceutical Industries and Associations (EFPIA) has released its annual W.A.I.T Indicator Survey - Once again, the report highlights significant disparities in the availability and accessibility of innovative medicines across Europe

SMC Backs 6 New Meds Including Mounjaro

The Scottish Medicines Consortium (SMC) has today announced its latest advice on six newly licensed medicines, covering a range of therapeutic areas including weight management, blood cancer, sickle cell disease, ulcerative colitis, and myelofibrosisNotable approvals include Eli Lilly’s Mounjaro (tirzepatide) and GSK’s Omjjara (momelotinib) Scotland has become the first country in the UK to back NHS use of the Eli Lilly therapy for weight management. Specifically, SMC recommended the therapy for weight loss and weight maintenance when accompanied by a reduced-calorie diet and increased physical activity

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!